Author:
Leonhardt U.,Seidensticker F.,Fussek M.,Stöckmann F.,Creutzfeldt W.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Creutzfeldt W. Pathogenesis of pancreatitis: the rationale for its treatment by inhibitors of enzyme activity and secretion. Biomed. Res. 1989; 10, Suppl. 1: 15–24.
2. Saluja AK, Saluja M, Printz H, Zavertnik A, Sengupta A, and Steer ML. Experimental pancreatitis is mediated by low-affinity cholecystokinin receptors that inhibit digestive enzyme secretion. Proc. Nat. Acad. Sci. USA 1989; 86: 8968–8971.
3. Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, and Setnikar I. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforsch. 1987; 37: 1265–1268.
4. Makovec F, Bani M, Cereda R, Chisté R, Revel L, Rovati LC, Setnikar I, and Rovati LA. Protective effect of CR-1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Peptides 1986; 7: 1159–1164.
5. Modlin IM, Bilchik AJ, Zucker KA, Adrian TE, Sussman J, and Graham SM. Cholecystokinin augmentation of ‘surgical’ pancreatitis. Benefits of receptor blockade. Arch. Surg. 1989; 124: 574–578.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献